logo-loader
viewBarclays PLC

Barclays says FCA investigating CEO Staley over Epstein links

The news came as the UK bank announced its final 2019 results, showing a profit before tax of £4.4bn

Barclays PLC -
Barclays CEO Jes Staley

Barclays PLC (LON:BARC) shares dropped on Thursday as the bank accompanied its full-year results although the bank with news the City's financial watchdog is carrying out an investigation into its chief executive Jes Staley's historical links with US billionaire sex offender Jeffrey Epstein.

The FTSE 100-listed lender said its usual performance assessments of its directors had made it aware of reports highlighting that Staley had a professional relationship with Epstein earlier in his career, but added that it remained confident in his ongoing leadership.

READ: A timeline of Barclays CEO Jes Staley

The bank said Staley had given an explanation of his relationship with Epstein to certain Barclays executives and the chairman last year, and then “confirmed to the board that he has had no contact whatsoever with Mr Epstein at any time since taking up his role as Barclays Group CEO in December 2015”.

The Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA) both launched an investigation last year, which the bank said was ongoing, into Staley's characterisation of his relationship with Epstein to Barclays and the subsequent description of that relationship in the company's response to the FCA.

An FCA spokesman said: “The FCA and PRA confirm there is an investigation concerning Mr Staley. We are unable to comment any further.”

Barclays said it believed Staley, who two years ago escaped with a fine but kept his job after regulators investigated his attempts to unmask an anonymous whistleblower at the bank, had been “sufficiently transparent” and so “retains the full confidence of the board”.

Full-year profits jump

The announcement was made in a separate statement alongside the UK high street bank’s annual results, which saw it post a profit before tax (PBT) of £4.4bn for 2019, up 26% on the previous year.

Profits were dented by £1.4bn of additional provisions for the historical misselling of payment protection insurance (PPI) after the government set a final deadline for claims last summer. 

Excluding litigation and conduct, Barclays PBT was £6.2bn, which was up 6% year-on-year and beat analyst consensus forecasts of £6.05bn.

The group proposed a final dividend of 6p, meaning the annual total will be increased by 38% to 9p, in line with market expectations.

Barclays' capital position was better than predicted, with its core tier 1 ratio ending the year at 13.8% compared to the average City forecast of 13.5%. 

However, the bank's board has backed away from its target of achieving return on tangible equity (ROTE) above 10% this year, saying “given global macroeconomic uncertainty and the current low-interest rate environment, it has become more challenging to achieve this in 2020” but still feel it can achieve “a meaningful improvement in returns”. 

Analysts at broker Shore Capital said the results were better than expected reflecting slightly better than expected performance on income, costs and impairments. 

“From a divisional perspective, Barclays UK and Consumer, Cards & Payments both reported adjusted profit slightly ahead of consensus expectations with the Corporate & Investment Bank slightly below (albeit with a beat in its Markets business),” the analysts said in a note to clients.

They noted that a meaningful improvement in returns in 2020, “which would still suggest significant upside risk to consensus which is currently looking for a return of just 8.5%”.

But Barclays shares were still down 3% to 173.60p in London, reflecting the worries over Staley's position.

   -- Updates share price --

Quick facts: Barclays PLC

Price: 96.8453 GBX

LSE:BARC
Market: LSE
Market Cap: £16.79 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences files patent application for its novel coronavirus...

Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of...

57 minutes ago

RNS

FORM 8.3 - ABBVIE PLC

13 hours, 45 minutes ago

FORM 8.3 - ALLERGAN PLC

13 hours, 46 minutes ago

FORM 8.5 (EPT/NON-RI) - HUNTSWORTH PLC

14 hours, 32 minutes ago

FORM 8.5 (EPT/NON-RI) - LOW & BONAR PLC

14 hours, 33 minutes ago

Form 8.3 - ABBVIE PLC AMENDMENT

1 day, 14 hours ago

Form 8.3 - ALLERGAN PLC AMENDMENT

1 day, 14 hours ago

FORM 8.3 - ABBVIE PLC - AMENDMENT

1 day, 14 hours ago

3 min read